Literature DB >> 8057464

Induction of feline immunodeficiency virus-specific cytotoxic T cells in vivo with carrier-free synthetic peptide.

J N Flynn1, C A Cannon, J A Beatty, M Mackett, M A Rigby, J C Neil, C Jarrett.   

Abstract

The role of cellular immunity in the establishment and progression of immunosuppressive lentivirus infection remains equivocal. To develop a model system with which these aspects of the host immune response can be studied experimentally, we examined the response of cats to a hybrid peptide containing predicted T-and B-cell epitopes from the gag and env genes of feline immunodeficiency virus (FIV). Cats were immunized with an unmodified 17-residue peptide incorporating residues 196 to 208 (from gag capsid protein p24) and 395 to 398 (from env glycoprotein gp120) of the FIV Glasgow-8 strain by using Quil A as an adjuvant. Virus-specific lymphocytotoxicity was measured by chromium-51 release assays. The target cells were autologous or allogeneic skin fibroblasts either infected with recombinant FIV gag vaccinia virus or pulsed with FIV peptides. Effector cells were either fresh peripheral blood mononuclear cells or T-cell lines stimulated with FIV peptides in vitro. Cytotoxic effector cells from immunized cats lysed autologous, but not allogeneic, target cells when they were either infected with recombinant FIV gag vaccinia virus or pulsed with synthetic peptides comprising residues 196 to 205 or 200 to 208 plus 395. Depletion of CD8+ T cells, from the effector cell population abrogated the lymphocytotoxicity. Immunized cats developed an antibody response to the 17-residue peptide immunogen and to recombinant p24. However, no antibodies which recognized smaller constituent peptides could be detected. This response correlated with peptide-induced T-cell proliferation in vitro. This study demonstrates that cytotoxic T lymphocytes specific for FIV can be induced following immunization with an unmodified short synthetic peptide and defines a system in which the protective or pathological role of such responses can be examined.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8057464      PMCID: PMC236988     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  39 in total

1.  T-cell antigenic sites tend to be amphipathic structures.

Authors:  C DeLisi; J A Berzofsky
Journal:  Proc Natl Acad Sci U S A       Date:  1985-10       Impact factor: 11.205

2.  Transfer of specific cytotoxic T lymphocytes protects mice inoculated with influenza virus.

Authors:  K L Yap; G L Ada; I F McKenzie
Journal:  Nature       Date:  1978-05-18       Impact factor: 49.962

3.  CD8-positive T lymphocytes specific for murine cytomegalovirus immediate-early antigens mediate protective immunity.

Authors:  M J Reddehase; W Mutter; K Münch; H J Bühring; U H Koszinowski
Journal:  J Virol       Date:  1987-10       Impact factor: 5.103

4.  Identification of a linear neutralization site within the third variable region of the feline immunodeficiency virus envelope.

Authors:  S Lombardi; C Garzelli; C La Rosa; L Zaccaro; S Specter; G Malvaldi; F Tozzini; F Esposito; M Bendinelli
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

5.  Cytotoxic T-cell immunity to influenza.

Authors:  A J McMichael; F M Gotch; G R Noble; P A Beare
Journal:  N Engl J Med       Date:  1983-07-07       Impact factor: 91.245

6.  T cell-mediated immunity to oncornavirus-induced tumors. II. Ability of different T cell sets to prevent tumor growth in vivo.

Authors:  J C Leclerc; H Cantor
Journal:  J Immunol       Date:  1980-02       Impact factor: 5.422

7.  HIV-specific cytotoxic T lymphocytes in seropositive individuals.

Authors:  B D Walker; S Chakrabarti; B Moss; T J Paradis; T Flynn; A G Durno; R S Blumberg; J C Kaplan; M S Hirsch; R T Schooley
Journal:  Nature       Date:  1987 Jul 23-29       Impact factor: 49.962

8.  Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques.

Authors:  S Chakrabarti; K Brechling; B Moss
Journal:  Mol Cell Biol       Date:  1985-12       Impact factor: 4.272

9.  Isolation of a T-lymphotropic virus from domestic cats with an immunodeficiency-like syndrome.

Authors:  N C Pedersen; E W Ho; M L Brown; J K Yamamoto
Journal:  Science       Date:  1987-02-13       Impact factor: 47.728

10.  Biological properties of an influenza A virus-specific killer T cell clone. Inhibition of virus replication in vivo and induction of delayed-type hypersensitivity reactions.

Authors:  Y L Lin; B A Askonas
Journal:  J Exp Med       Date:  1981-08-01       Impact factor: 14.307

View more
  10 in total

1.  Vaccination with inactivated virus but not viral DNA reduces virus load following challenge with a heterologous and virulent isolate of feline immunodeficiency virus.

Authors:  M J Hosie; T Dunsford; D Klein; B J Willett; C Cannon; R Osborne; J Macdonald; N Spibey; N Mackay; O Jarrett; J C Neil
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

2.  Vaccination with a feline immunodeficiency virus multiepitopic peptide induces cell-mediated and humoral immune responses in cats, but does not confer protection.

Authors:  J N Flynn; C A Cannon; J C Neil; O Jarrett
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

3.  Feline immunodeficiency virus vaccination: characterization of the immune correlates of protection.

Authors:  M J Hosie; J N Flynn
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

4.  Vaccination protects against in vivo-grown feline immunodeficiency virus even in the absence of detectable neutralizing antibodies.

Authors:  D Matteucci; M Pistello; P Mazzetti; S Giannecchini; D Del Mauro; L Zaccaro; P Bandecchi; F Tozzini; M Bendinelli
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

5.  Adoptive immunotherapy of feline immunodeficiency virus with autologous ex vivo-stimulated lymphoid cells modulates virus and T-cell subsets in blood.

Authors:  J Norman Flynn; Mauro Pistello; Patrizia Isola; Lucia Zaccaro; Barbara Del Santo; Enrica Ricci; Donatella Matteucci; Mauro Bendinelli
Journal:  Clin Diagn Lab Immunol       Date:  2005-06

6.  Immunization of cats against feline immunodeficiency virus (FIV) infection by using minimalistic immunogenic defined gene expression vector vaccines expressing FIV gp140 alone or with feline interleukin-12 (IL-12), IL-16, or a CpG motif.

Authors:  C M Leutenegger; F S Boretti; C N Mislin; J N Flynn; M Schroff; A Habel; C Junghans; S A Koenig-Merediz; B Sigrist; A Aubert; N C Pedersen; B Wittig; H Lutz
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

7.  A longitudinal study of feline immunodeficiency virus-specific cytotoxic T lymphocytes in experimentally infected cats, using antigen-specific induction.

Authors:  J A Beatty; B J Willett; E A Gault; O Jarrett
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

8.  Feline leukaemia virus: protective immunity is mediated by virus-specific cytotoxic T lymphocytes.

Authors:  J N Flynn; L Hanlon; O Jarrett
Journal:  Immunology       Date:  2000-09       Impact factor: 7.397

9.  Induction of feline immunodeficiency virus-specific cell-mediated and humoral immune responses following immunization with a multiple antigenic peptide from the envelope V3 domain.

Authors:  J N Flynn; C A Cannon; G Reid; M A Rigby; J C Neil; O Jarrett
Journal:  Immunology       Date:  1995-06       Impact factor: 7.397

10.  Three-color flow cytometry detection of virus-specific CD4+ and CD8+ T cells in the cat.

Authors:  Jolanda D F de Groot-Mijnes; Robbert G van der Most; Jessica M van Dun; Eddie G te Lintelo; Nancy M P Schuurman; Herman F Egberink; Raoul J de Groot
Journal:  J Immunol Methods       Date:  2004-02-01       Impact factor: 2.303

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.